Formulated for benign prostatic hyperplasia to manage urinary flow and support relief from obstructive symptoms.
Mechanism of Action
Terazosin selectively blocks postsynaptic alpha-1 adrenergic receptors. In the prostate and bladder neck, this results in smooth muscle relaxation, while in the vasculature, it causes peripheral dilation to lower blood pressure.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
24 hours
Contraindications
Hypersensitivity to terazosin, Hypersensitivity to other alpha-1 blockers
Severe Adverse Events
Syncope, Priapism, Angioedema — requires immediate medical attention
Information related to Terazosin Hydrochloride is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
